Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
|
|
Nurix Therapeutics, Inc. (NRIX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/14/2023 |
SC 13G/A
| Third Rock Ventures III, L.P. reports a 0.4% stake in Nurix Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| BAKER BROS. ADVISORS LP reports a 10% stake in Nurix Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| PRICE T ROWE ASSOCIATES INC reports a 6.9% stake in NURIX THERAPEUTICS INC |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/25/2023 |
SC 13G/A
| BlackRock Inc. reports a 8.8% stake in Nurix Therapeutics, Inc. |
| 02/14/2022 |
SC 13G/A
| Redmile Group, LLC reports a 6.6% stake in Nurix therapeutics, Inc. |
| 02/14/2022 |
SC 13G/A
| Third Rock Ventures III, L.P. reports a 5.7% stake in Nurix Therapeutics, Inc. |
| 02/14/2022 |
SC 13G/A
| PRICE T ROWE ASSOCIATES INC reports a 10.9% stake in Nurix Therapeutics, Inc. |
| 02/11/2022 |
SC 13G/A
| COLUMN GROUP L P reports a 1.5% stake in NURIX THERAPEUTICS, INC. |
| 02/11/2022 |
SC 13G/A
| Foresite Capital Fund IV, L.P. reports a 2.7% stake in Nurix Therapeutics, Inc. |
| 02/04/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/16/2021 |
SC 13G/A
| Foresite Capital Fund IV, L.P. reports a 8.4% stake in Nurix Therapeutics, Inc. |
| 02/04/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
|
|